Search company, investor...

Predict your next investment

Nittobo company logo
Corporation
nittobous.com

About Nittobo

Nittobo America Inc., NTB-A, bulk antisera, IgG, polyclonal antibodies, polyclonal antisera, immunodiagnostic assay, Turbidimetric, Midland BioProducts, International Immunology, IIC, MBC, polyclonal antiserum, IgM, IgA.nsw-23--suvpqel505f7pgeqv4580ba1hf3w92rev6zrb3okvo0w6qaxtyh-e-xrwnrabyjhven4godu8nbko3jpouogeblzh03rg6v46-8v-pr63zp4ge68jfv0022latso

Headquarters Location

25549 Adams Avenue

Murrieta, California, 92562,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Nittobo News

Nitto Boseki : Nittobo Group Integrated Report 2023 (KB)

Oct 24, 2023

(marketscreener.com) The Nittobo Group Integrated Report brings together financial information and sustainability-related information in one volume to provide stakeholders with a greater understanding of our medium- to long-term value creation structure, strategies, and specific initiatives. Attachments Original Link ...https://www.marketscreener.com/quote/stock/NITTO-BOSEKI-CO-LTD-6491956/news/Nitto-Boseki-Nittobo-Group-Integrated-Report-2023-65288-KB-65289-45130093/?utm_medium=RSS&utm_content=20231023

Nittobo Acquisitions

1 Acquisition

Nittobo acquired 1 company. Their latest acquisition was Capricorn Products on June 25, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/25/2019

$99M

Acquired

1

Date

6/25/2019

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.